Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gilead Sciences
Janssen Research & Development, LLC
Janssen Research & Development, LLC
University of Florida
Bristol-Myers Squibb
Daiichi Sankyo
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
University of Arizona
AstraZeneca
BicycleTx Limited
NRG Oncology
BeOne Medicines
Peking University First Hospital
Fujian Medical University Union Hospital
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Mayo Clinic
National Cancer Center, Korea
Columbia University
University Health Network, Toronto
Fox Chase Cancer Center
Relmada Therapeutics, Inc.
Medical University of Vienna
First Affiliated Hospital of Chongqing Medical University
The University of Hong Kong
Vasgene Therapeutics, Inc
Brown University
Hospital Centre Biel/Bienne
Hoosier Cancer Research Network
Zhujiang Hospital
Mabwell (Shanghai) Bioscience Co., Ltd.
Fudan University
RemeGen Co., Ltd.
RemeGen Co., Ltd.
Northwestern University